Redmile Group’s Arbutus Biopharma ABUS Stock Holding History

Redmile Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-700,000	Closed	-$12.2M	–	56
2015 Q1	$12.2M	Buy	+700,000	New	+$14.3M	1.1%	34

Other funds holding ABUS

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Redmile Group's ABUS Position: Q2 2015 in Review

Redmile Group sold out of Arbutus Biopharma (ABUS) in Q2 2015, closing a stake of 700,000 shares — an estimated $12.2M sold.

Redmile Group first reported a position in ABUS in Q1 2015 and held it in 1 quarter. The position peaked at $12.2M in Q1 2015. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

Redmile Group reported no remaining Arbutus Biopharma position as of Q2 2015 after selling out during the quarter.
Redmile Group sold 700,000 Arbutus Biopharma shares in Q2 2015, an estimated $12.2M.
Redmile Group first reported a position in Arbutus Biopharma in Q1 2015 and held it in 1 quarter.
Redmile Group's Arbutus Biopharma position peaked at $12.2M in Q1 2015.
63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on Redmile Group's 13F filing for Q2 2015, filed 14 Aug 2015.